Table 3 The selected cardio-oncology predictors of overall survival.

From: Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin

Evaluated factors

Univariate analysis

Multivariate analysis

HR

95%CI

p value

HR

95%CI

p value

Patients with pre-existing cardiovascular diseases (CVDs) vs patients without CVDs

0.999

0.79–1.27

0.996

0.998

0.77–1.29

0,99

Patients with heart failure as end of treatment with liposomal doxorubicin vs patients without this complication

1.31

0.73–2.33

0.36

1.08

0.59–1.98

0.8

Older age (≥ 60y vs < 60y)

1.04

0.83–1.30

0.76

1.19

0.93–1.53

0.17

Obesity (BMI ≥ 30 kg/m2 vs < 30 kg/m2)

0.76

0.57–1.01

0.054

0.85

0.63–1.14

0.28

Prognostically unbeneficial site of metastases

Central nervous system vs other sites

1.64

1.15–2.35

0.006

1.5

1.02–2.18

0.04

Liver vs other sites

1.33

1.06–1.66

0.01

1.43

1.12–1.83

0.004

Pericardium / myocardium vs other sites

2.25

0.83–6.06

0.11

2.06

0.74–5.76

0.17

Histopatological diagnosis of breast cancer

HER2 positive vs other diagnosis

1.38

1.06–1.82

0.02

1.28

0.95–1.73

0.11

Triple negative vs other diagnosis

1.28

0.92–1.79

0.14

1.15

0.8–1.66

0.45

Taxane-naive vs pretreated with taxanes

0.57

0.46–0.72

0.000002

0.8

0.59–1.07

0.14

Anthracycline—naive vs pretreated with anthracyclines

0.63

0.48–0.81

0.0004

0.79

0.55–1.14

0.21

Patients after left-sided radiotherapy vs others

1.27

0.99–1.64

0.06

1.02

0.78–1.33

0.9

Patients treated earlier with conventional doxorubicin dose ≥ 250 mg/m2 vs others

1.17

0.93–1.46

0.18

0.75

0.56–1.00

0.05

Characteristics of therapy with liposomal doxorubicin

First vs next line ofpalliative setting

0.53

0.42–0.66

 < 0.000001

0.82

0.61–1.11

0.2

Monotherapy vs combination with cyclophosphamide

1.31

0.996–1.74

0.05

1.01

0.74–1.39

0.9

Cumulative dose > 300 mg/m2 vs ≤ 300 mg/m2

0.53

0.42–0.67

 < 0.000001

0.61

0.47–0.78

0.0001

Subsequent anticancer therapy

Patients treated with cytostatics vs others

0.96

0.77–1.2

0.71

0.72

0.57–0.92

0.008

Patients treated with endocrine therapy vs others

0.56

0.44–0.72

0.000007

0.65

0.49–0.87

0.003

Back to article page